ACIUAC Immune SA

Nasdaq acimmune.com


$ 4.70 $ 0.09 (1.94 %)    

Thursday, 13-Jun-2024 15:59:55 EDT
QQQ $ 476.97 $ 2.57 (0.54 %)
DIA $ 386.89 $ -0.81 (-0.21 %)
SPY $ 542.45 $ 1.09 (0.2 %)
TLT $ 93.85 $ 1.36 (1.47 %)
GLD $ 212.97 $ -1.75 (-0.82 %)
$ 4.73
$ 4.69
$ 4.70 x 200
$ 0.00 x 0
$ 4.69 - $ 4.81
$ 1.90 - $ 5.14
214,755
na
469.21M
$ 1.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-initiates-coverage-on-ac-immune-with-buy-rating-announces-price-target-of-8

BTIG analyst Thomas Shrader initiates coverage on AC Immune (NASDAQ:ACIU) with a Buy rating and announces Price Target of $8.

 why-is-small-cap-alzheimers-focused-ac-immune-stock-trading-higher-on-monday

Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potenti...

Core News & Articles
Market-Moving News for May 13th
05/13/2024 12:42:15

GME: 46% | GameStop shares are trading higher amid possible retail investor interest following a social media post by Roaring K...

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

 ac-immune-received-decision-to-grant-european-patent-ep3735411-1345-tetrahydro-2h-pyrido43-bindole-derivatives-for-the-treatment-alleviation-or-prevention-of-disorders-associated-with-tau-aggregates-like-alzheimers-disease

https://register.epo.org/application?number=EP21153153

 ac-immune-raises-50m-its-alzheimers-targeting-immunotherapy-advances-into-phase-2b-trial

AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35...